Biohit Oyj (BIOBV.HE)

BIOBV.HE on Helsinki Stock Exchange

19 Dec 2014
Price Change (% chg)

€-0.05 (-1.03%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BIOBV.HE


Biohit Oyj is a Finland-based company engaged in the development, manufacture and marketing of diagnostic tests and analysis systems. The Company operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. It provides blood-sample... (more)
No analyst recommendations are available for BIOBV.HE.


Beta: 0.93
Market Cap (Mil.): €53.79
Shares Outstanding (Mil.): 11.16
Dividend: 0.72
Yield (%): 15.01


  BIOBV.HE Industry Sector
P/E (TTM): -- 37.83 38.47
EPS (TTM): -0.35 -- --
ROI: -26.22 18.99 18.25
ROE: -26.36 19.75 19.13
Search Stocks

BRIEF-Biohit and Doctagon have agreed to co-operate

* Biohit and Doctagon have agreed to co-operate thereby Doctagon will offer diagnostic tests by Biohit to its customers

12 Dec 2014

BRIEF-Biohit launches ColonView for colorectal cancer screening

* Says launches colonview - test for colorectal cancer screening

03 Nov 2014

BRIEF-Biohit names Niklas Nordström CFO

* Says Niklas Nordström has been appointed Chief Financial Officer (CFO) and member of Management team starting Nov. 3, 2014

03 Nov 2014

BRIEF-Biohit Q3 net sales down to EUR 1.2 mln

* Q3 net sales 1.2 million euros versus 1.3 million euros

23 Oct 2014

BRIEF-Biohit Oyj to sign an Acetium lozenge distribution agreement

Aug 15 - Biohit Oyj : * Biohit Oyj and Eastar Pharmaceuticals LLC to sign an Acetium lozenge

15 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks